VICTORIA RAMOS: Open Payments
NPI 1841704806 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$994 in 43 payments from 10 companies in 2025. Trend: 2023 $384 · 2024 $520 · 2025 $994
Food & beverage: $962Education: $32
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $429 |
| Madrigal Pharmaceuticals | 7 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Janssen Biotech, Inc. | 4 | $75 |
| PFIZER INC. | 2 | $46 |
| Novo Nordisk Inc | 2 | $41 |
| Braintree Laboratories, Inc. | 1 | $20 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Gilead Sciences, Inc. | 1 | $15 |
Products named: REZDIFFRA, SKYRIZI, LINZESS, TREMFYA, RINVOQ, CREON, Wegovy, ENTYVIO.
Industry payments across TX — which companies pay providers there.
